American Diabetes Association’s 80th Annual Scientific Sessions: #ADA2020

 

From Friday, June 12 to Tuesday, June 16th, the biggest diabetes conference of the year is taking place virtually – the American Diabetes Association’s 80th Annual Scientific Sessions (#ADA2020). This annual meeting brings together researchers, healthcare providers, diabetes technology companies and many more from around the globe. Originally set in Chicago, the ADA announced the shift to an all digital experience in light of the COVID-19 pandemic.

During these five days, there will be more than 1,800 Posters, 800 original research presentations and 200 virtual sessions covering the latest advancements in research, treatment, and care for people living with diabetes. That’s a lot of news to take in! Beyond Type 2 is doing the hard work for you: we’re reporting live from ADA 2020 and aggregating the most important industry and technological updates here. Check out our comprehensive review of the weekend + follow our minute by minute breaking news coverage on Twitter.

 

Breaking News From ADA 2020


Medtronic presented results from its U.S. pivotal trial of its investigational MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) system. Results of the 90-day showed improved A1C, Time in Range, and ...MORE

Diabetes Prevention Program Shows Persistent Reduction of Type 2 Diabetes Development


A 22-year follow up on the Diabetes Prevention Program Outcomes Study (DPPOS) indicates a continued significant reduction in the participants’ risk of developing Type 2 diabetes. Individuals in the...MORE

Lifestyle Interventions for Type 2 Diabetes Remission


Type 2 diabetes remission is a hot topic within the T2D community. At the American Diabetes Association's 80th Scientific Sessions, researchers presented data on the impact lifestyle intervention...MORE

Disparities in Diabetes and Diabetes Care—What Can We Do About It?


At this ADA 2020 session, systemic racism and implicit bias were clear contributors to poor health and healthcare outcomes for Black and Latinx communities.MORE

Dapagliflozin May Reduce the Onset of Type 2 Diabetes


Research presented at the American Diabetes Association's 80th Scientific Sessions revealed that the SGLT-2 Inhibitor, dapagliflozin, may reduce the onset of Type 2 diabetes when used in patients...MORE

Who Has Access to New Oral Diabetes Medications?


Racial and ethnic minorities may have a greater need for newer diabetes medications but functionally have less access. MORE

FreeStyle Libre 2 Approved for Use in U.S.


The FreeStyle Libre 2 is a 14 day CGM system that transmits data every minute and now includes customizable high and low alerts without the need to scan the device. The Abbott announcement says it wil...MORE

Nationwide Study in France Shows Dramatic Drop in DKA in Type 1 and Type 2 after Starting on FreeStyle Libre


The study included more that 70,000 patients living with diabetes and DKA rates were reduced by 52% for patients with T1D and 47% for patients with T2D.MORE

Closed Loop Updates: Omnipod Horizon and Medtronic 780G data presented at ADA 2020


Data from four new clinical trials involving Hybrid Closed Loop systems, Medtronic 780G and Omnipod 5 Powered by Horizon was presented at ADA 2020.MORE

News From DiabetesMine™ D-Data Exchange 2020


The Beyond Type 2 team is spending a day at The DiabetesMine™ D-Data ExChange – this is our report from this enlightening event. MORE